Department of Tumor Immunology; Radboud University Medical Centre and Nijmegen Centre for Molecular Life Sciences; Nijmegen, The Netherlands.
Oncoimmunology. 2012 Mar 1;1(2):234-236. doi: 10.4161/onci.1.2.18126.
Platinum-based anticancer drugs enhance the immunostimulatory potential of DCs and decrease the immunosuppressive capacity of tumor cells. This immunomodulatory ability is based on the inhibition of STAT6-mediated expression of co-inhibitory molecule PD-L2 and opens up the possibility of using these drugs in combination with other immunostimulatory compounds.
基于铂类的抗癌药物增强了 DC 的免疫刺激潜能,并降低了肿瘤细胞的免疫抑制能力。这种免疫调节能力基于抑制 STAT6 介导的共抑制分子 PD-L2 的表达,为这些药物与其他免疫刺激化合物联合使用开辟了可能性。